Non-Vitamin K antagonist oral anticoagulants (NOACs): Clinical evidence and therapeutic considerations

Postgraduate Medical Journal

Volumn 90, Issue 1067, 2014, Pages 520-528

  Saraf, Karan ^a   Morris, Paul ^a,b   Garg, Pankaj ^a   Sheridan, Paul ^a,b   Storey, Robert ^a,b  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; FIBRIN; FIBRINOGEN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT AGENT; RIVAROXABAN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOEMBOLIC STROKE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; EVIDENCE BASED PRACTICE; GASTROESOPHAGEAL REFLUX; HUMAN; LICENSING; NAUSEA AND VOMITING; ORTHOPEDIC SURGERY; PHASE 3 CLINICAL TRIAL (TOPIC); PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DABIGATRAN; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FACTOR XA INHIBITORS; HUMANS; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84906354978     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2014-132605     Document Type: Review

References (44)

1. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on anti- thrombotic and thrombolytic therapy. Chest 2005;127:415-16.
2. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
3. Mitka M. FDA advisory decision highlights some problems inherent in pragmatic trials. JAMA 2011;306:1851-2.
4. Rose AJ, Ozonoff A, Henault LE, et al. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008;6:1647-54.
5. Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014;111:781-2.
6. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978;17:1371-7.
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
8. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-2.
9. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
10. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long term multicentre observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 2014;128:237-43.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
12. Schulman S, Kakkar AK, Schellong SM, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). American Society of Hematology 2011 Annual Meeting; 12 December, 2011; San Diego, CA. Abstract 205.
13. Bauersachs R, Berkowitz SD, Brenner B, et al.; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
14. Buller HR, Prins MH, Lensin AW, et al.; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366: 1287-97.
15. Agnelli G, Buller HR, Cohen A, et al. Apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
16. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85.
17. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
18. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75.
19. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double blind trial. Lancet 2010;375:807-15.
20. Conolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
21. Lassen MR, Gallus A, Raskob JE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98.
22. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-65.
23. Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acute ill medical patients. N Engl J Med 2013;368:513-28.
24. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN extension study). Expert Rev Cardiovasc Ther 2011;9:841-4.
25. http://guidance.nice.org.uk/TA249 (accessed 23 May 2014).
26. http://guidance.nice.org.uk/TA256 (accessed 23 May 2014).
27. http://guidance.nice.org.uk/TA261 (accessed 23 May 2014).
28. http://guidance.nice.org.uk/TA275 (accessed 23 May 2014).
29. Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012;98:573-8.
30. Harrington AR, Armstrong EP, Nolan PE, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81.
31. Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110: 845-51.
32. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J 2011;32:1968-76.
33. http://www.ema.europa.eu/ema (accessed 19 Nov 2013).
34. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9.
35. Gavillet M, Angelillo-Scherrer A. Quantification of the anticoagulatory effect of noval anticoagulants and management of emergencies. Cardiovasc Med 2012;15:170-9.
36. Lu G, DeGuzman FR, Karbarz MJ, et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-antidote, PRT064445). Eur Heart J 2011;32:640-1.
37. Mega JL, Braunwald E, Wiviott S, et al. Rivaroxaban in patients with recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
38. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
39. http://news.bms.com/press-release/partnering-news/new-eliquis-apixaban-posthoc-subanalysis-phase-iii-aristotle-trial-de (accessed 23 May 2014).
40. Eikelboom JW, Conolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14.
41. http://clinicaltrials.gov/ct2/show/NCT01868243 (accessed 23 May 2014).
42. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
43. Kawaji H, Ishii M, Tamaki Y, et al. Edoxaban for prevention of venous thromboembolism after major orthopedic surgery. Orthop Res Rev 2012;4:53-64.
44. De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (section i). Position paper of the ESC working group on thrombosis-task force on anticoagulants in heart disease. Thromb Haemost 2013;109:569-79.